CAMEO+ eventHEALTH2026-04-24馃嚭馃嚫
FDA approves review process for three psychedelic drugs after Trump directive
source: U.S. Food and Drug Administration -> target: Three companies studying psychedelic medications
On 2026-04-24, the U.S. Food and Drug Administration issued national priority vouchers to three companies to help fast-track review of potential psychedelic medications. The companies are studying psilocybin and methylone for conditions including treatment-resistant depression, major depressive disorder, and PTSD.
0.21Significance3.0Magnitude0.3Systemic0.4Market2Articles
Location
Silver SpringMarylandNorth AmericaUnited StatesNorth America38.991, -77.026
Story Links
cameoplus_health 路 2026-04-24 路 2 articles
FDA approves review process for three psychedelic drugs after Trump directive
cameoplus_health 路 2026-04-24 路 2 articles
FDA to conduct ultra-fast review of three psychedelic drugs after Trump directive
cameoplus_health 路 2026-04-25 路 1 articles
FDA plans ultra-fast review of three psychedelic drugs after Trump directive
cameoplus_health 路 2026-04-24 路 1 articles
FDA fast-tracks psilocybin and other psychedelics for depression and PTSD